Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance.

Animals Bridged Bicyclo Compounds, Heterocyclic / pharmacology Clustered Regularly Interspaced Short Palindromic Repeats / genetics Lymphoma / drug therapy Mice Proto-Oncogene Proteins c-bcl-2 / genetics Proto-Oncogene Proteins c-myc / metabolism Sulfonamides

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
12 08 2022
Historique:
received: 29 08 2021
accepted: 29 07 2022
entrez: 12 8 2022
pubmed: 13 8 2022
medline: 17 8 2022
Statut: epublish

Résumé

CRISPR technologies have advanced cancer modelling in mice, but CRISPR activation (CRISPRa) methods have not been exploited in this context. We establish a CRISPRa mouse (dCas9a-SAM

Identifiants

DOI: 10.1038/s41467-022-32485-9 PMID: 35961968 PMC: PMC9374748
pubmed: 35961968
doi: 10.1038/s41467-022-32485-9
pii: 10.1038/s41467-022-32485-9
pmc: PMC9374748
doi:

Substances chimiques

Bridged Bicyclo Compounds, Heterocyclic 0
Proto-Oncogene Proteins c-bcl-2 0
Proto-Oncogene Proteins c-myc 0
Sulfonamides 0
venetoclax N54AIC43PW

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4739

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2022. The Author(s).

Références

Pickar-Oliver, A. & Gersbach, C. A. The next generation of CRISPR-Cas technologies and applications. Nat. Rev. Mol. Cell Biol. 20, 490–507 (2019).
pubmed: 31147612 pmcid: 7079207 doi: 10.1038/s41580-019-0131-5
Aoyama, T. & Chua, N. H. A glucocorticoid-mediated transcriptional induction system in transgenic plants. Plant J. 11, 605–612 (1997).
pubmed: 9107046 doi: 10.1046/j.1365-313X.1997.11030605.x
Maeder, M. L. et al. CRISPR RNA-guided activation of endogenous human genes. Nat. Methods 10, 977–979 (2013).
pubmed: 23892898 pmcid: 3794058 doi: 10.1038/nmeth.2598
Mali, P. et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat. Biotechnol. 31, 833–838 (2013).
pubmed: 23907171 pmcid: 3818127 doi: 10.1038/nbt.2675
Perez-Pinera, P. et al. RNA-guided gene activation by CRISPR-Cas9–based transcription factors. Nat. Methods 10, 973–976 (2013).
pubmed: 23892895 pmcid: 3911785 doi: 10.1038/nmeth.2600
Gilbert, L. A. et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442–451 (2013).
pubmed: 23849981 pmcid: 3770145 doi: 10.1016/j.cell.2013.06.044
Chavez, A. et al. Highly efficient Cas9-mediated transcriptional programming. Nat. Methods 12, 326–328 (2015).
pubmed: 25730490 pmcid: 4393883 doi: 10.1038/nmeth.3312
Gilbert, L. A. et al. Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell 159, 647–661 (2014).
pubmed: 25307932 pmcid: 4253859 doi: 10.1016/j.cell.2014.09.029
Konermann, S. et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517, 583–588 (2015).
pubmed: 25494202 doi: 10.1038/nature14136
Tanenbaum Marvin, E. et al. A Protein-Tagging System for Signal Amplification in Gene Expression and Fluorescence Imaging. Cell 159, 635–646 (2014).
pubmed: 25307933 pmcid: 4252608 doi: 10.1016/j.cell.2014.09.039
Ventura, A. & Dow, L. E. Modeling Cancer in the CRISPR Era. Annu. Rev. Cancer Biol. 2, 111–131 (2018).
doi: 10.1146/annurev-cancerbio-030617-050455
Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
pubmed: 10647931 doi: 10.1016/S0092-8674(00)81683-9
Potts, M. A., McDonald, J. A., Sutherland, K. D. & Herold, M. J. Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy. Eur. J. Immunol. 50, 1871–1884 (2020).
pubmed: 33202035 doi: 10.1002/eji.202048712
Aukema, S. M. et al. Double-hit B-cell lymphomas. Blood 117, 2319–2331 (2011).
pubmed: 21119107 doi: 10.1182/blood-2010-09-297879
Johnson, N. A. et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 114, 2273–2279 (2009).
pubmed: 19597184 pmcid: 2745846 doi: 10.1182/blood-2009-03-212191
Liu, Y., Azizian, N. G., Dou, Y., Pham, L. V. & Li, Y. Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma. J. Hematol. Oncol. 12, 119 (2019).
pubmed: 31752970 pmcid: 6868798 doi: 10.1186/s13045-019-0803-9
Leskov, I. et al. Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies. Oncogene 32, 1066–1072 (2013).
pubmed: 22484426 doi: 10.1038/onc.2012.117
Pallasch, C. P. et al. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell 156, 590–602 (2014).
pubmed: 24485462 pmcid: 3975171 doi: 10.1016/j.cell.2013.12.041
Strasser, A., Harris, A. W., Bath, M. L. & Cory, S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348, 331–333 (1990).
pubmed: 2250704 doi: 10.1038/348331a0
Ravà M, et al. Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC/BCL2 double-hit B cell lymphoma. Sci Transl Med 10, (2018).
Chen B-J, Fend F, Campo E, Quintanilla-Martinez L. Aggressive B-cell lymphomas—from morphology to molecular pathogenesis. Annals of Lymphoma 3, (2019).
Merino, D. et al. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. Cancer Cell 34, 879–891 (2018).
pubmed: 30537511 doi: 10.1016/j.ccell.2018.11.004
Guièze, R. et al. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell 36, 369–384.e313 (2019).
pubmed: 31543463 pmcid: 6801112 doi: 10.1016/j.ccell.2019.08.005
Thijssen, R. et al. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood 137, 2721–2735 (2021).
pubmed: 33824975 pmcid: 8138548 doi: 10.1182/blood.2020010167
Lois, C., Hong, E. J., Pease, S., Brown, E. J. & Baltimore, D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 295, 868–872 (2002).
pubmed: 11786607 doi: 10.1126/science.1067081
Adams, J. M. et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318, 533–538 (1985).
pubmed: 3906410 doi: 10.1038/318533a0
Aubrey, B. J. et al. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep. 10, 1422–1432 (2015).
pubmed: 25732831 doi: 10.1016/j.celrep.2015.02.002
Kelly, G. L. et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev. 28, 58–70 (2014).
pubmed: 24395247 pmcid: 3894413 doi: 10.1101/gad.232009.113
Kotschy, A. et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature 538, 477–482 (2016).
pubmed: 27760111 doi: 10.1038/nature19830
Thai, T. H. et al. Regulation of the germinal center response by microRNA-155. Science 316, 604–608 (2007).
pubmed: 17463289 doi: 10.1126/science.1141229
Low, M. S. Y. et al. IRF4 Activity Is Required in Established Plasma Cells to Regulate Gene Transcription and Mitochondrial Homeostasis. Cell Rep. 29, 2634–2645.e2635 (2019).
pubmed: 31775034 doi: 10.1016/j.celrep.2019.10.097
Michalak, E. M. et al. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis. Cell Death Differ. 16, 684–696 (2009).
pubmed: 19148184 doi: 10.1038/cdd.2008.195
Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844–848 (2004).
pubmed: 14704432 doi: 10.1126/science.1092472
Gebauer, N. et al. TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations. Leuk. Lymphoma 56, 179–185 (2015).
pubmed: 24679006 doi: 10.3109/10428194.2014.907896
Strasser, A., Harris, A. W., Huang, D. C., Krammer, P. H. & Cory, S. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. Embo j. 14, 6136–6147 (1995).
pubmed: 8557033 pmcid: 394738 doi: 10.1002/j.1460-2075.1995.tb00304.x
Ng, A. P. et al. An Erg-driven transcriptional program controls B cell lymphopoiesis. Nat. Commun. 11, 3013 (2020).
pubmed: 32541654 pmcid: 7296042 doi: 10.1038/s41467-020-16828-y
Zhuang, Y. et al. Altered pathways and targeted therapy in double hit lymphoma. J. Hematol. Oncol. 15, 26 (2022).
pubmed: 35303910 pmcid: 8932183 doi: 10.1186/s13045-022-01249-9
Bolomsky, A. et al. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. J. Hematol. Oncol. 13, 173 (2020).
pubmed: 33308268 pmcid: 7731749 doi: 10.1186/s13045-020-01007-9
Sanson, K. R. et al. Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities. Nat. Commun. 9, 5416 (2018).
pubmed: 30575746 pmcid: 6303322 doi: 10.1038/s41467-018-07901-8
Sánchez-Rivera, F. J. & Jacks, T. Applications of the CRISPR-Cas9 system in cancer biology. Nat. Rev. Cancer 15, 387–395 (2015).
pubmed: 26040603 pmcid: 4530801 doi: 10.1038/nrc3950
Chavez, A. et al. Comparison of Cas9 activators in multiple species. Nat. Methods 13, 563–567 (2016).
pubmed: 27214048 pmcid: 4927356 doi: 10.1038/nmeth.3871
Hunt, C. et al. Tissue-specific activation of gene expression by the Synergistic Activation Mediator (SAM) CRISPRa system in mice. Nat. Commun. 12, 2770 (2021).
pubmed: 33986266 pmcid: 8119962 doi: 10.1038/s41467-021-22932-4
Qin, J. Y. et al. Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. PLoS One 5, e10611 (2010).
pubmed: 20485554 pmcid: 2868906 doi: 10.1371/journal.pone.0010611
Zhou, H. et al. In vivo simultaneous transcriptional activation of multiple genes in the brain using CRISPR-dCas9-activator transgenic mice. Nat. Neurosci. 21, 440–446 (2018).
pubmed: 29335603 doi: 10.1038/s41593-017-0060-6
Matharu N, et al. CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency. Science 363, (2019).
Gemberling, M. P. et al. Transgenic mice for in vivo epigenome editing with CRISPR-based systems. Nat. Methods 18, 965–974 (2021).
pubmed: 34341582 pmcid: 8349887 doi: 10.1038/s41592-021-01207-2
Friedberg, J. W. How I treat double-hit lymphoma. Blood 130, 590–596 (2017).
pubmed: 28600333 doi: 10.1182/blood-2017-04-737320
Zhang, W. et al. Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma. BMC Cancer 20, 714 (2020).
pubmed: 32736575 pmcid: 7393908 doi: 10.1186/s12885-020-07198-1
Uchida, A. et al. Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements. Haematologica 104, 1417–1421 (2019).
pubmed: 30523053 pmcid: 6601100 doi: 10.3324/haematol.2018.204958
Davids, M. S. et al. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J. Clin. Oncol. 35, 826–833 (2017).
pubmed: 28095146 pmcid: 5455685 doi: 10.1200/JCO.2016.70.4320
Moujalled, D. M. et al. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia 33, 905–917 (2019).
pubmed: 30214012 doi: 10.1038/s41375-018-0261-3
Roberts, A. W. et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med 374, 311–322 (2016).
pubmed: 26639348 doi: 10.1056/NEJMoa1513257
DiNardo, C. D. et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135, 791–803 (2020).
pubmed: 31932844 pmcid: 7068032 doi: 10.1182/blood.2019003988
Boiko, S. et al. Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas. Blood 137, 2947–2957 (2021).
pubmed: 33259592 pmcid: 8160501 doi: 10.1182/blood.2020008528
Schenk, R. L. et al. Characterisation of mice lacking all functional isoforms of the pro-survival BCL-2 family member A1 reveals minor defects in the haematopoietic compartment. Cell Death Differ. 24, 534–545 (2017).
pubmed: 28085150 pmcid: 5344213 doi: 10.1038/cdd.2016.156
Tuzlak, S. et al. The BCL-2 pro-survival protein A1 is dispensable for T cell homeostasis on viral infection. Cell Death Differ. 24, 523–533 (2017).
pubmed: 28085151 pmcid: 5344212 doi: 10.1038/cdd.2016.155
Kueh, A. J. et al. An update on using CRISPR/Cas9 in the one-cell stage mouse embryo for generating complex mutant alleles. Cell Death Differ. 24, 1821–1822 (2017).
pubmed: 28753205 pmcid: 5596424 doi: 10.1038/cdd.2017.122
Herold, M. J., van den Brandt, J., Seibler, J. & Reichardt, H. M. Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats. Proc. Natl Acad. Sci. USA 105, 18507–18512 (2008).
pubmed: 19017805 pmcid: 2587564 doi: 10.1073/pnas.0806213105
Dai, Z. et al. edgeR: a versatile tool for the analysis of shRNA-seq and CRISPR-Cas9 genetic screens. F1000Res 3, 95 (2014).
pubmed: 24860646 pmcid: 4023662
McCarthy, D. J., Chen, Y. & Smyth, G. K. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res 40, 4288–4297 (2012).
pubmed: 22287627 pmcid: 3378882 doi: 10.1093/nar/gks042
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43, e47 (2015).
pubmed: 25605792 pmcid: 4402510 doi: 10.1093/nar/gkv007
Liao, Y., Smyth, G. K. & Shi, W. The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. Nucleic Acids Res 47, e47 (2019).
pubmed: 30783653 pmcid: 6486549 doi: 10.1093/nar/gkz114
Chen, Y., Lun, A. T. & Smyth, G. K. From reads to genes to pathways: differential expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline. F1000Res 5, 1438 (2016).
pubmed: 27508061 pmcid: 4934518
Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).
pubmed: 24485249 pmcid: 4053721 doi: 10.1186/gb-2014-15-2-r29
Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3, Article3 (2004).
Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J. R. Stat. Soc.: Ser. B (Methodol.) 57, 289–300 (1995).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
pubmed: 16199517 pmcid: 1239896 doi: 10.1073/pnas.0506580102
Wu, D. & Smyth, G. K. Camera: a competitive gene set test accounting for inter-gene correlation. Nucleic Acids Res 40, e133 (2012).
pubmed: 22638577 pmcid: 3458527 doi: 10.1093/nar/gks461
Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380–381 (2015).
pubmed: 25924071 doi: 10.1038/nmeth.3364
Bullard, J. H., Purdom, E., Hansen, K. D. & Dudoit, S. Evaluation of statistical methods for normalization and differential expression in mRNA-Seq experiments. BMC Bioinforma. 11, 94 (2010).
doi: 10.1186/1471-2105-11-94
Deng Y, et al. Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance. GitHub, https://doi.org/10.5281/zenodo.6816211 (2022).

Auteurs

Yexuan Deng (Y)

The State Key Laboratory of Pharmaceutical Biotechnology, Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, China.
The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.

Sarah T Diepstraten (ST)

The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.

Margaret A Potts (MA)

The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.
ORCID: 0000-0001-9796-9683

Göknur Giner (G)

The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.

Stephanie Trezise (S)

The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.
ORCID: 0000-0002-7511-3291

Ashley P Ng (AP)

The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.
ORCID: 0000-0001-9690-0879

Gerry Healey (G)

The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.

Serena R Kane (SR)

The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.

Amali Cooray (A)

The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.
ORCID: 0000-0003-2981-9282

Kira Behrens (K)

The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.
ORCID: 0000-0003-0800-8472

Amy Heidersbach (A)

Department of Molecular Biology, Genentech, Inc., South San Francisco, CA, USA.

Andrew J Kueh (AJ)

The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.

Martin Pal (M)

The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.
School of Dentistry and Medical Sciences, Charles Sturt University, Wagga Wagga, NSW, Australia.
ORCID: 0000-0002-1563-5426

Stephen Wilcox (S)

The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.

Lin Tai (L)

The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.

Warren S Alexander (WS)

The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.

Jane E Visvader (JE)

The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.
ORCID: 0000-0001-9173-6977

Stephen L Nutt (SL)

The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.
ORCID: 0000-0002-0020-6637

Andreas Strasser (A)

The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.
ORCID: 0000-0002-5020-4891

Benjamin Haley (B)

Department of Molecular Biology, Genentech, Inc., South San Francisco, CA, USA.

Quan Zhao (Q)

The State Key Laboratory of Pharmaceutical Biotechnology, Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, China.
ORCID: 0000-0002-8533-1938

Gemma L Kelly (GL)

The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.
ORCID: 0000-0002-6533-1201

Marco J Herold (MJ)

The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia. herold@wehi.edu.au.
Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia. herold@wehi.edu.au.
ORCID: 0000-0001-7539-7581

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Generation of a CRISPR activation mouse that...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques, cycle ponté › Composés hétérocycliques bicycliques › Generation of a CRISPR activation mouse that...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Séquences répétées en tandem › Clustered regularly interspaced short palindromic repeats › Generation of a CRISPR activation mouse that...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › Generation of a CRISPR activation mouse that...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Generation of a CRISPR activation mouse that...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Protéines proto-oncogènes c-bcl-2 › Generation of a CRISPR activation mouse that...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription à motif basique hélice-boucle-hélice › Protéines proto-oncogènes c-myc › Generation of a CRISPR activation mouse that...
questionsmedicales.fr › Composés chimiques organiques › Composés du soufre › Sulfones › Sulfonamides › Generation of a CRISPR activation mouse that...